SCHEMBL3215490

SCHEMBL3215490

C=C(C)CCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.43
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CA1 P00915 3/20 0.41
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
GAA P10253 1/20 0.39
CYP2D6 P10635 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PSMD10 O75832 1/20 0.38
CA2 P00918 2/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14730788 0.85 MAPT (0.43) ALDH1A1KMT2AL3MBTL1
SCHEMBL17763488 0.85 STAT3 (0.47) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL14773015 0.83 STAT3 (0.43) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL5870519 0.83 STAT3 (0.51) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL10592620 0.83 ALDH1A1 (0.43) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL31677496 0.83 STAT3 (0.40) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL8022421 0.83 STAT3 (0.46) STAT3ALDH1A1KMT2ACA1CA12
Ethylene SCHEMBL4379131 0.82 CA1 (0.50) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
Ethylene SCHEMBL3466431 0.82 CA1 (0.50) STAT3ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL241884 0.82 CA1 (0.52) STAT3ALDH1A1KMT2ACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60038337-A None JP disclosed
US-20240417388-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-12-19 US disclosed
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-08 US disclosed
CN-118561812-A Benzimidazolone-derived BCL6 inhibitors 癌症研究科技有限公司 2024-08-30 CN disclosed
EP-3630291-B9 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-05-29 EP disclosed
EP-4374858-A2 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-29 EP disclosed
CN-111163839-B Benzimidazolone-derived BCL6 inhibitors 癌症研究科技有限公司 2024-05-28 CN disclosed
EP-3630291-B1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-01-10 EP disclosed
US-20230348488-A1 SECO-AMBRAKETALS SYMRISE AG (DE) 2023-11-02 US disclosed
US-20210147382-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-20 US disclosed
EP-1109817-B1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INST NAT SANTE RECH MED (FR) 2002-06-05 EP disclosed
EP-1109818-A1 PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-06-27 EP disclosed
EP-1109817-A1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-06-27 EP disclosed
WO-2000012516-A1 PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2000-03-09 WO disclosed
WO-2000012519-A1 PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2000-03-09 WO disclosed
EP-0691327-B1 AMINE DERIVATIVE AND DERMATOLOGIC PREPARATION CONTAINING THE SAME KAO CORP (JP) 1999-07-21 EP disclosed
US-5723497-A AMINE ALCOHOL DERIVATIVES FOR WRINKLE RESISTNCE KAO CORPORATION (JP) 1998-03-03 US disclosed
EP-0691327-A1 AMINE DERIVATIVE AND DERMATOLOGIC PREPARATION CONTAINING THE SAME Kao Corporation (JP) 1996-01-10 EP disclosed
JP-S6038337-A PRODUCTION OF 6-METHYL-6-HEPTEN-2-ONE KONAN KAKO KK 1985-02-27 JP disclosed
US-4308273-A 1,6-Naphthyridine derivatives, and antidinic and cerebral circulation improver containing such derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1981-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348488-A1 SECO-AMBRAKETALS AREG, CUTA, TAAR5 STAT3 4865/4885ALDH1A1 1626/4885KMT2A 4039/4885
US-20210147382-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 BCL6, BCL6B, BCL3 STAT3 138/4885ALDH1A1 1654/4885KMT2A 752/4885
US-20240417388-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 BCL6, BCL6B, BCL3 STAT3 138/4885ALDH1A1 1654/4885KMT2A 752/4885
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 BCL6, BCL6B, BCL3 STAT3 138/4885ALDH1A1 1654/4885KMT2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.